Treatment of Post-poliomyelitis Syndrome by Intravenous Immunoglobulin

Completed

• Conditions: Post-Poliomyélitis Syndrom

• Registration Number: NCT04004390
• Lead Sponsor: University Hospital, Montpellier

Brief Summary

Our study evaluates the efficacy of IGIV treatment in PPS on clinical (walking and pain) and isokinetic (muscle strength) criteria, on patients with PS at Montpellier's Hospital

Detailed Description

Patients are admitted to a multidisciplinary consultation (neurologist, PMK) to validate the indication of treatment with IGIV. Realization of a pre-therapeutic evaluation in the department of MPR on the criteria of judgment, then the patient is admitted in a service of neurology to benefit from the cure of IGIV. The patient is then re-admitted to a PMR service for post-treatment evaluation.

Collection of data retrospectively.

Study Timeline

• Study Start: 2019-06-28
• Study First Submitted: 2019-06-28
• Study First Submitted QC: 2019-06-28
• Study First Posted: 2019-07-02
• Primary Completion: 2019-12-01
• Study Completion: 2019-12-30
• Status Verified: 2020-03
• Last Update Submitted: 2020-03-09
• Last Update Posted: 2020-03-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 17

Inclusion Criteria

• Diagnosis of PPS
• Pre- and post-therapeutic evaluation carried out
• Data transcribed in the computerized patient file

Exclusion Criteria

• No walking patient

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Muscular strength	5 months	Muscular strength with isokinetic

Secondary Outcome Measures

Name	Time	Method
Walking perimeter	5 months	Walking perimeter with walking test (6 minutes)

Trial Locations

Locations (1)

Uh Montpellier; 🇫🇷 Montpellier, France